Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Olga Czabak
Observed names:
Czabak, Olga,
O. Czabak
Institution:
Medical University of Lublin
Observed institution:
Medical University of Lublin
ORCID:
0000-0002-9083-9058
Observed ORCID:
0000-0002-9083-9058
OpenAlex ID:
A5014769795
Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial
2023
·
Dominik Dytfeld
, Tomasz Wróbel
, et al.
·
The Lancet Oncology
·
86
PDF
Mass spectrometry–based assessment of M protein in peripheral blood during maintenance therapy in multiple myeloma
2024
·
Tadeusz Kubicki
, Dominik Dytfeld
, et al.
·
Blood
·
43
PDF
Carfilzomib, lenalidomide, and dexamethasone compared with lenalidomide treatment after autologous haematopoietic stem-cell transplantation in patients with multiple myeloma (ATLAS): primary analysis of a randomised, open-label, phase 3 trial
2026
·
Dominik Dytfeld
, Tomasz Wróbel
, et al.
·
The Lancet Haematology
·
6
Longitudinal Assessment of Minimal Residual Disease (MRD) in the ATLAS Randomized Phase 3 Trial of Post-Transplant Treatment with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus Lenalidomide (R) Alone in Patients with Newly Diagnosed Multiple Myeloma (NDMM)
2023
·
Tadeusz Kubicki
, Dominik Dytfeld
, et al.
·
Blood
·
5
Innowacyjna terapia CAR-T w leczeniu nowotworów hematologicznych — wybrane aspekty genetyczne i immunologiczne
2020
·
Katarzyna Karwicka
, Joanna Wawer
, et al.
·
Hematologia
·
5
PDF
Carfilzomib, lenalidomide, and dexamethasone (KRd) as maintenance therapy after autologous stem-cell transplantation (ASCT) in patients with newly diagnosed multiple myeloma (NDMM).
2025
·
Andrzej J. Jakubowiak
, Tomasz Wrobel
, et al.
·
Journal of Clinical Oncology
·
4
Treatment patterns of patients with triple-class exposed refractory/relapsed multiple myeloma in Poland — preliminary results of multicentre observational POMOST study
2025
·
Norbert Grząśko
, Beata Wałachowska
, et al.
·
Acta Haematologica Polonica
·
3
Health-related quality of life in patients with multiple myeloma treated in the phase 3 ATLAS trial of post-transplant maintenance with carfilzomib, lenalidomide, dexamethasone or lenalidomide alone
2024
·
Tadeusz Kubicki
, Krzysztof Jamroziak
, et al.
·
Polskie Archiwum Medycyny Wewnętrznej
·
3
Polyclonal immunoglobulin recovery in patients with newly diagnosed myeloma receiving maintenance therapy after autologous haematopoietic stem cell transplantation with either carfilzomib, lenalidomide and dexamethasone or lenalidomide alone: Subanalysis of the randomized phase 3 ATLAS trial
2023
·
Tadeusz Kubicki
, Dominik Dytfeld
, et al.
·
British Journal of Haematology
·
3
PDF
ATLAS: A phase 3 randomized trial of carfilzomib, lenalidomide, and dexamethasone versus lenalidomide alone after stem-cell transplant for multiple myeloma.
2022
·
Dominik Dytfeld
, Tomasz Wrobel
, et al.
·
Journal of Clinical Oncology
·
3
Efficacy of ixazomib-lenalidomide-dexamethasone in high-molecular-risk relapsed/refractory multiple myeloma – case series and literature review
2021
·
Aneta Szudy-Szczyrek
, Sylwia Chocholska
, et al.
·
Annals of Agricultural and Environmental Medicine
·
3
PDF
Mass Spectrometry-Based Assessment of M-Protein in Peripheral Blood during Maintenance Therapy in Multiple Myeloma (MM) in the Phase III ATLAS Trial
2023
·
Tadeusz Kubicki
, Dominik Dytfeld
, et al.
·
Blood
·
2
Czy zaburzenia snu i senność w ciągu dnia wpływają na wyrównanie metaboliczne cukrzycy? Badanie z zastosowaniem wybranych narzędzi diagnostycznych
2013
·
Dominika Kowalczyk
, Olga Czabak
, et al.
·
Family Medicine & Primary Care Review
·
2
OAB-010: Atlas: a phase 3 randomized trial of carfilzomib, lenalidomide, and dexamethasone versus lenalidomide alone after stem-cell transplant for multiple myeloma
2022
·
Andrzej Jakubowiak
, Tomasz Wrobel
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
·
1
S175: Atlas: a Phase 3 Randomized Trial of Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma
2022
·
D. Dytfeld
, T. Wróbel
, et al.
·
HemaSphere
·
1
RAEB II type of myelodysplastic syndrome associated with axillary abscesses – Case Report
2021
·
Bożena Sokołowska
, Daria Majowicz
, et al.
·
Annals of Agricultural and Environmental Medicine
·
1
PDF
Rare case of Richter’s syndrome localization in liver and thyroid of a patient with a chronic lymphocytic leukemia (CLL) – Case report and literature
2019
·
Ewa Wąsik-Szczepanek
, Agnieszka Szymczyk
, et al.
·
Annals of Agricultural and Environmental Medicine
·
1
PDF
Carfilzomib, Lenalidomide, and Dexamethasone (KRd) after Autologous Stem-Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma: Analysis of High-Risk Subset in Phase 3 ATLAS Trial
2025
·
Andrzej Jakubowiak
, Tomasz Wrobel
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
KD-PACE chemotherapy regimen as a salvage therapy for aggressive, refractory multiple myeloma
2025
·
Maciej Dubaj
, Karol Bigosiński
, et al.
·
Acta Haematologica Polonica
PDF
Health-Related Quality of Life in Polish Patients with Multiple Myeloma Treated in the Phase 3 ATLAS Trial of Post-Transplant Maintenance with Carfilzomib, Lenalidomide, Dexamethasone or Lenalidomide Alone
2023
·
Tadeusz Kubicki
, Ben A Derman
, et al.
·
Blood
P-397 Polyclonal immunoglobulin recovery in myeloma patients receiving maintenance after autologous hematopoietic stem cell transplantation with carfilzomib, lenalidomide and dexamethasone or lenalidomide
2023
·
Tadeusz Kubicki
, Dominik Dytfeld
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
Show more works
View as search
Works count:
22
Citation count:
173
H-index:
5
I10-index:
2
Year
Topic
Type